Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, Citigroup Analyst Says

Key Points

• Citigroup has raised its price target for Regeneron Pharmaceuticals stock to $660.00, indicating a potential upside of 19.34% from its current price and maintaining a "buy" rating for the biopharmaceutical company.
• The stock's recent performance showed a decline of 2.1%, with shares trading around $553.03 despite strong earnings, reporting $12.89 earnings per share which surpassed analysts' expectations.
• Despite the recent price fluctuation, the consensus among analysts is a "Moderate Buy" with a collective price target averaging $817.88, showing optimism about Regeneron's future potential.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) had its price objective lifted by equities research analysts at Citigroup from $650.00 to $660.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm currently has a "buy" rating on the biopharmaceutical company's stock. Citigroup's target price indicates a potential upside of 19.34% from the company's current price.

A number of other research analysts also recently commented on the stock. Truist Financial decreased their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating for the company in a research report on Monday, August 11th. Weiss Ratings reissued a "hold (c-)" rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 8th. UBS Group reissued a "neutral" rating on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Argus downgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, June 30th. Finally, Canaccord Genuity Group reissued a "buy" rating and issued a $850.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, July 23rd. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $817.88.

Regeneron Pharmaceuticals Stock Down 2.1%

Regeneron Pharmaceuticals stock traded down $11.60 during mid-day trading on Monday, reaching $553.03. The company's stock had a trading volume of 649,798 shares, compared to its average volume of 1,103,726. The company has a market capitalization of $58.62 billion, a price-to-earnings ratio of 13.94, a price-to-earnings-growth ratio of 1.80 and a beta of 0.31. Regeneron Pharmaceuticals has a 12 month low of $476.49 and a 12 month high of $1,024.36. The business's 50 day simple moving average is $573.95 and its 200 day simple moving average is $564.02. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business had revenue of $3.68 billion during the quarter, compared to the consensus estimate of $3.30 billion. During the same quarter last year, the firm earned $11.56 earnings per share. The firm's revenue for the quarter was up 3.6% compared to the same quarter last year. As a group, research analysts anticipate that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company's stock valued at $5,966,767,000 after purchasing an additional 121,545 shares during the last quarter. State Street Corp boosted its stake in shares of Regeneron Pharmaceuticals by 0.9% in the 2nd quarter. State Street Corp now owns 4,832,002 shares of the biopharmaceutical company's stock valued at $2,536,801,000 after purchasing an additional 42,343 shares during the last quarter. Dodge & Cox boosted its stake in Regeneron Pharmaceuticals by 64.6% during the second quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company's stock worth $2,008,799,000 after acquiring an additional 1,502,198 shares in the last quarter. Franklin Resources Inc. boosted its stake in Regeneron Pharmaceuticals by 1.6% during the second quarter. Franklin Resources Inc. now owns 2,313,496 shares of the biopharmaceutical company's stock worth $1,214,585,000 after acquiring an additional 36,821 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in Regeneron Pharmaceuticals by 4.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,175,026 shares of the biopharmaceutical company's stock worth $1,379,467,000 after acquiring an additional 89,579 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.